The claim that GLPs affect muscle and bone is scientifically supported at a high evidence tier. A major 2025 clinical advisory from four leading medical organizations explicitly documents muscle and bone loss as a recognized challenge during GLP-1 therapy, and two active human clinical trials are currently investigating these effects in older adults and those with diabetes. While the creator did not cite a specific study, the concept is firmly grounded in current clinical practice and emerging research.
Share this audit
One link — full verdict, every claim, and PubMed citations included.
Shareable link includes the full verdict, claims, and PubMed citations.
Post captionshow
Comment ADAM and I’ll send you everything you need to know about the peptide and muscle loss truth every woman over 40 needs to hear.
I sat down with fitness expert, IFBB Pro, and co-host of the Mind Pump podcast Adam Schafer (@mindpumpadam ) because we need to talk about the use of peptides in women over 40 and I wasn’t leaving without real answers.
What GLPs are actually doing to muscle and bo…
Show full post caption
ne. Why the scale and the mirror are both lying to you. How you can be doing everything right, hitting your protein, lifting heavy, training five days a week, and still be destroying your body from the inside out. We also got into the gray market peptide industry, eating disorder screening, diet culture, and the question nobody is asking before handing these things out. I’m not anti-peptide. I’m not anti-GLP-1. I just think women deserve the full conversation, not just the benefits, not just the before and afters, but the real tradeoffs that nobody’s talking about. If you’ve ever felt like the peptide conversation was missing something... This episode is for you. Comment ADAM and I’ll send it straight to your DMs.
Show lessVideo transcript not captured. This audit used the caption only. For a fuller audit, run a new check and paste the spoken transcript.
Claim breakdown
1 claim“GLPs are doing things to muscle and bone.”
Multiple credible sources confirm GLPs affect muscle and bone tissue. A 2025 joint advisory from the American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association, and The Obesity Society (Mozaffarian et al., Obesity. 2025;33(8):1475-1503) explicitly identifies 'muscle and bone loss' as a documented challenge during GLP-1 treatment. Two active Phase 3/4 human clinical trials are currently investigating these effects: NCT06861439 ('Effects of Tirzepatide on Fat-Free Mass, Bone and Physical Function in Older Adults') and NCT07428746 ('Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes'). The evidence tier is high—human trials and expert clinical consensus acknowledge this as a real, measurable phenomenon requiring nutritional and lifestyle intervention.
Supporting studies
- 1
Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society
Obesity (Silver Spring, Md.) · 2025·PMID 40445127
- 2
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Diabetes care · 2024·PMID 38843460
- 3
GLP-1 Receptor Agonists
The New England journal of medicine · 2026·PMID 41931049
- 4
Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies
Diabetes, obesity & metabolism · 2024·PMID 38937282
- 5
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation
Metabolism: clinical and experimental · 2024·PMID 39481534
- 6
Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity
Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025·PMID 39295512
- 7
The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care
Current reviews in musculoskeletal medicine · 2025·PMID 40372699
- 8
Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society
Obesity pillars · 2025·PMID 40673264
This audit is for educational purposes only. Not medical advice. Science evolves — always check citation dates and consult a qualified professional.
Report an error